These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 19922456)

  • 1. Transthyretin as a potential CSF biomarker for Alzheimer's disease and dementia with Lewy bodies: effects of treatment with cholinesterase inhibitors.
    Schultz K; Nilsson K; Nielsen JE; Lindquist SG; Hjermind LE; Andersen BB; Wallin A; Nilsson C; Petersén A
    Eur J Neurol; 2010 Mar; 17(3):456-60. PubMed ID: 19922456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.
    Luo X; Hou L; Shi H; Zhong X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chan J; Chen X; Fang Y; Wu F; He H; Ning Y
    J Neurochem; 2013 Dec; 127(5):681-90. PubMed ID: 23800322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease.
    Reesink FE; Lemstra AW; van Dijk KD; Berendse HW; van de Berg WD; Klein M; Blankenstein MA; Scheltens P; Verbeek MM; van der Flier WM
    J Alzheimers Dis; 2010; 22(1):87-95. PubMed ID: 20847452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias.
    Bibl M; Mollenhauer B; Lewczuk P; Esselmann H; Wolf S; Trenkwalder C; Otto M; Stiens G; Rüther E; Kornhuber J; Wiltfang J
    Mol Psychiatry; 2007 Jul; 12(7):671-80. PubMed ID: 17339876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amyloid pathology influences aβ1-42 cerebrospinal fluid levels in dementia with lewy bodies.
    Slaets S; Le Bastard N; Theuns J; Sleegers K; Verstraeten A; De Leenheir E; Luyckx J; Martin JJ; Van Broeckhoven C; Engelborghs S
    J Alzheimers Dis; 2013; 35(1):137-46. PubMed ID: 23364139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies.
    Mollenhauer B; Steinacker P; Bahn E; Bibl M; Brechlin P; Schlossmacher MG; Locascio JJ; Wiltfang J; Kretzschmar HA; Poser S; Trenkwalder C; Otto M
    Neurodegener Dis; 2007; 4(5):366-75. PubMed ID: 17622779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal lobar degeneration.
    Ishiki A; Kamada M; Kawamura Y; Terao C; Shimoda F; Tomita N; Arai H; Furukawa K
    J Neurochem; 2016 Jan; 136(2):258-61. PubMed ID: 26485083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CSF tau, Aβ42, and MHPG differentiate dementia with Lewy bodies from Alzheimer's disease.
    Aerts MB; Esselink RA; Claassen JA; Abdo WF; Bloem BR; Verbeek MM
    J Alzheimers Dis; 2011; 27(2):377-84. PubMed ID: 21841257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered CSF orexin and α-synuclein levels in dementia patients.
    Wennström M; Londos E; Minthon L; Nielsen HM
    J Alzheimers Dis; 2012; 29(1):125-32. PubMed ID: 22207004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative analysis of transthyretin, tau and amyloid-beta in patients with dementia.
    Gloeckner SF; Meyne F; Wagner F; Heinemann U; Krasnianski A; Meissner B; Zerr I
    J Alzheimers Dis; 2008 May; 14(1):17-25. PubMed ID: 18525124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease.
    Noguchi-Shinohara M; Tokuda T; Yoshita M; Kasai T; Ono K; Nakagawa M; El-Agnaf OM; Yamada M
    Brain Res; 2009 Jan; 1251():1-6. PubMed ID: 19071095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CSF amyloid-β peptides in neuropathologically diagnosed dementia with Lewy bodies and Alzheimer's disease.
    Mollenhauer B; Esselmann H; Trenkwalder C; Schulz-Schaeffer W; Kretzschmar H; Otto M; Wiltfang J; Bibl M
    J Alzheimers Dis; 2011; 24(2):383-91. PubMed ID: 21297274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum and cerebrospinal fluid levels of transthyretin in Lewy body disorders with and without dementia.
    Maetzler W; Tian Y; Baur SM; Gauger T; Odoj B; Schmid B; Schulte C; Deuschle C; Heck S; Apel A; Melms A; Gasser T; Berg D
    PLoS One; 2012; 7(10):e48042. PubMed ID: 23133543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer's disease.
    Mollenhauer B; Bibl M; Trenkwalder C; Stiens G; Cepek L; Steinacker P; Ciesielczyk B; Neubert K; Wiltfang J; Kretzschmar HA; Poser S; Otto M
    J Neural Transm (Vienna); 2005 Jul; 112(7):933-48. PubMed ID: 15937638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders.
    Spies PE; Melis RJ; Sjögren MJ; Rikkert MG; Verbeek MM
    J Alzheimers Dis; 2009; 16(2):363-9. PubMed ID: 19221426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of cholinesterase inhibitor therapy for dementia: comparison of Alzheimer's disease and Dementia with Lewy bodies.
    Gustavsson A; Van Der Putt R; Jönsson L; McShane R
    Int J Geriatr Psychiatry; 2009 Oct; 24(10):1072-8. PubMed ID: 19639600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF Mg and Ca as diagnostic markers for dementia with Lewy bodies.
    Boström F; Hansson O; Gerhardsson L; Lundh T; Minthon L; Stomrud E; Zetterberg H; Londos E
    Neurobiol Aging; 2009 Aug; 30(8):1265-71. PubMed ID: 18191875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
    Parnetti L; Tiraboschi P; Lanari A; Peducci M; Padiglioni C; D'Amore C; Pierguidi L; Tambasco N; Rossi A; Calabresi P
    Biol Psychiatry; 2008 Nov; 64(10):850-5. PubMed ID: 18395699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease.
    Gómez-Tortosa E; Gonzalo I; Fanjul S; Sainz MJ; Cantarero S; Cemillán C; Yébenes JG; del Ser T
    Arch Neurol; 2003 Sep; 60(9):1218-22. PubMed ID: 12975286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.